NC
Nexthera Capital Portfolio holdings
AUM
$120M
This Quarter Return
+0.36%
1 Year Return
+20.18%
3 Year Return
+117.79%
5 Year Return
–
10 Year Return
–
AUM
$371M
AUM Growth
+$371M
(-13%)
Cap. Flow
-$38.2M
Cap. Flow
% of AUM
-10.32%
Top 10 Holdings %
Top 10 Hldgs %
60.06%
Holding
69
New
23
Increased
15
Reduced
11
Closed
15
Top Buys
| 1 |
Bausch Health
BHC
|
$14M |
| 2 |
BOLD
Audentes Therapeutics, Inc
BOLD
|
$11.9M |
| 3 |
ARQL
Arqule Inc
ARQL
|
$9.83M |
| 4 |
Viatris
VTRS
|
$9.65M |
| 5 |
TherapeuticsMD
TXMD
|
$8.58M |
Top Sells
| 1 |
TSRO
TESARO, Inc.
TSRO
|
$19.3M |
| 2 |
Pacira BioSciences
PCRX
|
$18.2M |
| 3 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$16.5M |
| 4 |
CLLS
Cellectis
CLLS
|
$15.5M |
| 5 |
Sangamo Therapeutics
SGMO
|
$15.2M |
Sector Composition
| 1 | Healthcare | 91.98% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Exelixis
EXEL
$10.1B
| $30.7M | 5.89% | 1,735,030 +313,430 | +22% | +$5.55M |
|
|
AGN
2
DELISTED
Allergan plc
AGN
| $30.2M | 5.79% | 158,712 -63,401 | -29% | -$12.1M |
|
|
IMMU
3
DELISTED
Immunomedics Inc
IMMU
| $29.1M | 5.58% | 1,398,577 +69,473 | +5% | +$1.45M |
|
|
4
Viatris
VTRS
$12.3B
| $25.5M | 4.88% | 695,788 +263,779 | +61% | +$9.65M |
|
|
DOVA
5
DELISTED
Dova Pharmaceuticals, Inc. Common Stock
DOVA
| $21.5M | 4.13% | 1,026,906 +206,558 | +25% | +$4.33M |
|
|
BOLD
6
DELISTED
Audentes Therapeutics, Inc
BOLD
| $21.4M | 4.11% | 541,172 +299,672 | +124% | +$11.9M |
|
|
GBT
7
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $20.9M | 4% | 549,231 +145,139 | +36% | +$5.52M |
|
|
TVRD
8
Tvardi Therapeutics, Inc. Common Stock
TVRD
$281M
| $17.7M | 3.38% | 737,303 +301,503 | +69% | +$7.22M |
|
|
9
Bausch Health
BHC
$2.74B
| $14M | 2.68% | +545,500 | New | +$14M |
|
|
ECYT
10
DELISTED
Endocyte, Inc. Common Stock
ECYT
| $11.6M | 2.23% | 654,532 +58,532 | +10% | +$1.04M |
|
11
Abeona Therapeutics
ABEO
$350M
| $10.9M | 2.09% | 849,979 +223,175 | +36% | +$2.86M |
|
|
CBAY
12
DELISTED
Cymabay Therapeutics
CBAY
| $10.1M | 1.93% | 908,664 +80,009 | +10% | +$887K |
|
|
ARQL
13
DELISTED
Arqule Inc
ARQL
| $9.83M | 1.88% | +1,737,397 | New | +$9.83M |
|
|
STML
14
DELISTED
Stemline Therapeutics, Inc.
STML
| $9.66M | 1.85% | 582,070 +22,553 | +4% | +$374K |
|
15
Gyre Therapeutics
GYRE
$703M
| $9.62M | 1.84% | 892,579 +105,714 | +13% | +$1.14M |
|
16
Insmed
INSM
$28.8B
| $9.39M | 1.8% | 464,159 -182,704 | -28% | -$3.69M |
|
|
17
TherapeuticsMD
TXMD
$12.8M
| $8.58M | 1.64% | +1,307,100 | New | +$8.58M |
|
18
Nektar Therapeutics
NKTR
$568M
| $7.8M | 1.5% | +128,000 | New | +$7.8M |
|
19
AstraZeneca
AZN
$248B
| $7.65M | 1.47% | 193,279 -327,000 | -63% | -$12.9M |
|
|
ACHN
20
DELISTED
Achillion Pharmaceuticals, Inc.
ACHN
| $5.83M | 1.12% | +1,583,954 | New | +$5.83M |
|
21
Viking Therapeutics
VKTX
$3.04B
| $5.71M | 1.09% | +327,730 | New | +$5.71M |
|
22
Kura Oncology
KURA
$686M
| $5.45M | 1.04% | 311,536 -69,923 | -18% | -$1.22M |
|
|
FOMX
23
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
| $4.28M | 0.82% | +747,308 | New | +$4.28M |
|
|
ZSAN
24
DELISTED
Zosano Pharma Corporation
ZSAN
| $4.23M | 0.81% | 1,033,759 +333,759 | +48% | +$1.37M |
|
25
Sutro Biopharma
STRO
$72.7M
| $3.47M | 0.67% | +231,613 | New | +$3.47M |
|